2seventy bio (TSVT) News Today $5.00 0.00 (0.00%) As of 05/13/2025 Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TSVT Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period 2seventy bio, Inc. (NASDAQ:TSVT) Shares Acquired by Western Standard LLCWestern Standard LLC increased its position in 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) by 175.7% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 788,350 shares of the company's stock after purchasing an additional 502,419 sharesMay 22, 2025 | marketbeat.comStonepine Capital Management LLC Has $882,000 Stock Position in 2seventy bio, Inc. (NASDAQ:TSVT)Stonepine Capital Management LLC raised its position in 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) by 200.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 300,000 shares of the company's stMay 20, 2025 | marketbeat.comDimensional Fund Advisors LP Has $1.40 Million Holdings in 2seventy bio, Inc. (NASDAQ:TSVT)Dimensional Fund Advisors LP raised its holdings in 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) by 68.6% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 475,118 shares of the company's stock after buying an additionalMay 18, 2025 | marketbeat.comMadison Avenue Partners LP Sells 1,983,327 Shares of 2seventy bio, Inc. (NASDAQ:TSVT)Madison Avenue Partners LP lessened its holdings in 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) by 77.4% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 579,895 shares of the company's stock after selling 1,983,327May 16, 2025 | marketbeat.com2seventy bio (NASDAQ:TSVT) Given "Sell (D-)" Rating at Weiss RatingsWeiss Ratings reiterated a "sell (d-)" rating on shares of 2seventy bio in a research note on Saturday.May 12, 2025 | marketbeat.comEngine Capital Management LP Sells 585,977 Shares of 2seventy bio, Inc. (NASDAQ:TSVT)Engine Capital Management LP trimmed its holdings in shares of 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) by 45.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 703,972 shares of the company's stock after selMay 11, 2025 | marketbeat.comDAFNA Capital Management LLC Sells 200,777 Shares of 2seventy bio, Inc. (NASDAQ:TSVT)DAFNA Capital Management LLC cut its stake in 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) by 31.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 429,252 shares of the company's stock after selling 200,777May 10, 2025 | marketbeat.com2seventy bio (TSVT) Projected to Post Quarterly Earnings on Wednesday2seventy bio (NASDAQ:TSVT) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 14. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-14-2seventy-bio-inc-stock/)May 9, 2025 | marketbeat.com2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers SquibbMay 7, 2025 | businesswire.comSusquehanna Fundamental Investments LLC Makes New Investment in 2seventy bio, Inc. (NASDAQ:TSVT)Susquehanna Fundamental Investments LLC acquired a new stake in shares of 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 93,480 shares of the company's stock, valued at apMay 7, 2025 | marketbeat.com2seventy bio, Inc. (NASDAQ:TSVT) Shares Sold by Marshall Wace LLPMarshall Wace LLP cut its position in 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) by 41.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 275,536 shares of the company's stock after selling 193,34May 3, 2025 | marketbeat.com2seventy bio, Inc. (NASDAQ:TSVT) Given Average Recommendation of "Hold" by BrokeragesShares of 2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) have been given an average rating of "Hold" by the seven research firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, one hMay 1, 2025 | marketbeat.com2seventy bio (NASDAQ:TSVT) Earns Sell (E+) Rating from Weiss RatingsWeiss Ratings reiterated a "sell (e+)" rating on shares of 2seventy bio in a research report on Thursday.April 27, 2025 | marketbeat.com2seventy bio, Inc. (NASDAQ:TSVT) Sees Significant Drop in Short Interest2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) was the target of a large decline in short interest in March. As of March 31st, there was short interest totalling 2,750,000 shares, a decline of 16.9% from the March 15th total of 3,310,000 shares. Currently, 5.8% of the company's stock are sold short. Based on an average daily volume of 1,180,000 shares, the short-interest ratio is currently 2.3 days.April 21, 2025 | marketbeat.com2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVTApril 16, 2025 | businesswire.comWeiss Ratings Reiterates Sell (D-) Rating for 2seventy bio (NASDAQ:TSVT)Weiss Ratings reissued a "sell (d-)" rating on shares of 2seventy bio in a research report on Tuesday.April 10, 2025 | marketbeat.com2seventy bio, Inc. (NASDAQ:TSVT) Given Average Rating of "Hold" by BrokeragesShares of 2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) have been assigned an average rating of "Hold" from the eight analysts that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendaApril 5, 2025 | marketbeat.com2seventy bio, Inc. (NASDAQ:TSVT) Short Interest Update2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) saw a significant drop in short interest in March. As of March 15th, there was short interest totalling 3,310,000 shares, a drop of 31.0% from the February 28th total of 4,800,000 shares. Based on an average trading volume of 1,000,000 shares, the short-interest ratio is presently 3.3 days. Currently, 7.0% of the company's stock are short sold.March 31, 2025 | marketbeat.com2seventy Bio reports Q4 EPS (37c) vs ($1.11) last yearMarch 27, 2025 | markets.businessinsider.com2seventy bio (NASDAQ:TSVT) Announces Earnings Results, Misses Expectations By $0.11 EPS2seventy bio (NASDAQ:TSVT - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.11). 2seventy bio had a negative net margin of 207.25% and a negative return on equity of 53.65%.March 26, 2025 | marketbeat.com2seventy bio Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 25, 2025 | businesswire.com2seventy bio's (TSVT) Sell (E+) Rating Reiterated at Weiss RatingsWeiss Ratings reissued a "sell (e+)" rating on shares of 2seventy bio in a report on Saturday.March 24, 2025 | marketbeat.com2seventy bio, Inc. (NASDAQ:TSVT) COO Jessica Snow Sells 2,298 Shares2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) COO Jessica Snow sold 2,298 shares of the business's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $4.95, for a total transaction of $11,375.10. Following the completion of the sale, the chief operating officer now directly owns 254,193 shares of the company's stock, valued at $1,258,255.35. This represents a 0.90 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.March 20, 2025 | marketbeat.comInsider Selling: 2seventy bio, Inc. (NASDAQ:TSVT) CFO Sells 2,592 Shares of Stock2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) CFO Victoria Eatwell sold 2,592 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $4.95, for a total value of $12,830.40. Following the completion of the sale, the chief financial officer now owns 444,387 shares in the company, valued at approximately $2,199,715.65. The trade was a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.March 20, 2025 | marketbeat.comWilliam D. Baird III Sells 5,092 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) Stock2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) CEO William D. Baird III sold 5,092 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $4.95, for a total value of $25,205.40. Following the sale, the chief executive officer now owns 1,121,034 shares in the company, valued at $5,549,118.30. The trade was a 0.45 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.March 20, 2025 | marketbeat.comJessica Snow Sells 2,298 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) StockMarch 20, 2025 | insidertrades.comMonimus Capital Management LP Invests $775,000 in 2seventy bio, Inc. (NASDAQ:TSVT)Monimus Capital Management LP bought a new position in 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 263,644 shares of the company's stock, valued at approximatMarch 16, 2025 | marketbeat.comMorgan Stanley Lowers 2seventy bio (NASDAQ:TSVT) Price Target to $5.00Morgan Stanley decreased their target price on shares of 2seventy bio from $6.00 to $5.00 and set an "equal weight" rating on the stock in a research note on Friday.March 15, 2025 | marketbeat.comInsider Selling: 2seventy bio, Inc. (NASDAQ:TSVT) Major Shareholder Sells 5,142,111 Shares of Stock2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) major shareholder Global Healthcare Master Kynam sold 5,142,111 shares of the firm's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $4.93, for a total value of $25,350,607.23. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.March 14, 2025 | marketbeat.com2seventy Bio price target lowered to $5 from $6 at Morgan StanleyMarch 14, 2025 | markets.businessinsider.com2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVTMarch 14, 2025 | businesswire.com2seventy bio, Inc. (NASDAQ:TSVT) Major Shareholder Sells $25,350,607.23 in StockMarch 14, 2025 | insidertrades.com2seventy bio (NASDAQ:TSVT) Downgraded to Hold Rating by Leerink PartnrsLeerink Partnrs downgraded 2seventy bio from a "strong-buy" rating to a "hold" rating in a research note on Tuesday.March 14, 2025 | marketbeat.comBiotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & MoreMarch 13, 2025 | msn.com$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of 2seventy bio, Inc. - TSVTMarch 12, 2025 | prnewswire.com2seventy bio (NASDAQ:TSVT) Given Market Perform Rating at Leerink PartnersLeerink Partners reissued a "market perform" rating and issued a $5.00 target price (down previously from $9.00) on shares of 2seventy bio in a report on Tuesday.March 12, 2025 | marketbeat.comShareholder Alert: The Ademi Firm investigates whether 2seventy bio, Inc. is obtaining a Fair Price for its Public ShareholdersMarch 11, 2025 | businesswire.comTSVT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of 2seventy bio, Inc. Is Fair to ShareholdersMarch 11, 2025 | tmcnet.com2seventy Bio to be acquired by Bristol Myers for $5.00 per share in cashMarch 11, 2025 | markets.businessinsider.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc.March 11, 2025 | prnewswire.com1,254,827 Shares in 2seventy bio, Inc. (NASDAQ:TSVT) Acquired by Regeneron Pharmaceuticals Inc.Regeneron Pharmaceuticals Inc. acquired a new position in 2seventy bio, Inc. (NASDAQ:TSVT - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 1,254,827 shares of the company's stock, vMarch 11, 2025 | marketbeat.com2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers SquibbMarch 10, 2025 | businesswire.com2seventy bio, Inc. (NASDAQ:TSVT) Given Consensus Recommendation of "Moderate Buy" by Brokerages2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six analysts that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating, two have assigned a buMarch 10, 2025 | marketbeat.com2seventy bio (NASDAQ:TSVT) Receives Sell (D-) Rating from Weiss RatingsWeiss Ratings reissued a "sell (d-)" rating on shares of 2seventy bio in a research report on Friday.March 8, 2025 | marketbeat.com2seventy bio to Participate in the 2025 TD Cowen Healthcare ConferenceFebruary 25, 2025 | finance.yahoo.com2seventy bio to Participate in the 2025 TD Cowen Healthcare ConferenceFebruary 25, 2025 | businesswire.com2seventy bio (TSVT) Projected to Post Earnings on Tuesday2seventy bio (NASDAQ:TSVT) will be releasing earnings before the market opens on Tuesday, March 4.February 25, 2025 | marketbeat.comWeiss Ratings Reiterates "Sell (D-)" Rating for 2seventy bio (NASDAQ:TSVT)Weiss Ratings reaffirmed a "sell (d-)" rating on shares of 2seventy bio in a research note on Wednesday.February 20, 2025 | marketbeat.com2seventy bio, Inc. (NASDAQ:TSVT) Given Average Rating of "Moderate Buy" by Brokerages2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the six ratings firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold ratinFebruary 13, 2025 | marketbeat.comCiti cuts 2Seventy Bio stock target to $9, maintains Buy ratingFebruary 6, 2025 | msn.com Get 2seventy bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TSVT and its competitors with MarketBeat's FREE daily newsletter. Email Address TSVT Media Mentions By Week TSVT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TSVT News Sentiment▼0.000.68▲Average Medical News Sentiment TSVT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TSVT Articles This Week▼02▲TSVT Articles Average Week Get 2seventy bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TSVT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CureVac News Today Mineralys Therapeutics News Today Phibro Animal Health News Today Arcus Biosciences News Today Wave Life Sciences News Today Syndax Pharmaceuticals News Today Collegium Pharmaceutical News Today Enliven Therapeutics News Today Spyre Therapeutics News Today Nurix Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TSVT) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhy 2026 will be a disaster for many Americans2025 Market Crash The first-quarter stock crash left investors wondering what lies ahead. Today 50-year Wal...Chaikin Analytics | SponsoredTrump’s treachery This might just be the greatest time in America to be an energy company. Since taking office in 2025, Presi...Porter & Company | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 2seventy bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 2seventy bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TSVT Stock Free TSVT Stock Alerts